Investing.com - Stifel在 Compass Pathways (NASDAQ:CMPS) 举办其COMP360裸盖菇治疗投资者活动后，重申了"买入"评级和11.00美元的目标价。目前7.82美元的股价较Stifel的目标价有41%的上涨空间，而 InvestingPro 数据显示，该股交易价接近其52周高点7.87美元，过去六个月内实现了126%的价格回报。

Investing.com - Cantor Fitzgerald在 Compass Pathways (NASDAQ:CMPS) 即将发布其COMP360治疗方案的第三阶段更新前夕，重申了其"超配"评级和20.00美元的目标价。该目标价较目前7.82美元的价格有显著上涨空间，该股目前交易价接近其52周高点7.87美元。 InvestingPro 数据显示，CMPS仅在过去一周就上涨了13.33% ...

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be launch-ready by the end of the year if approved. Compass recently held a ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has ...

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...

Screening closed for all sites and final participants being scheduled for dosing On track for top-line 6-week primary endpoint results in late Q2 LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731175223/en/ The articles, information, and content displayed on this webpage ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June To date, the COMP005 trial is the largest, ...